NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC₅₀s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway^[1].

MitoNEET^[1]

NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC₅₀s of 29.48 µM, 94.26 µM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC₅₀ values of around 60 µM for NL-1^[1].
NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death^[1].
NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

335.46

C₁₈H₂₅NO₃S

188532-26-5

Room temperature in continental US; may vary elsewhere.

DMSO : 250 mg/mL (745.25 mM; Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

  Solubility: ≥ 2.08 mg/mL (6.20 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (6.20 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: ≥ 2.08 mg/mL (6.20 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (6.20 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90% corn oil

  Solubility: ≥ 2.08 mg/mL (6.20 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (6.20 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

• [1]. Geldenhuys WJ, et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34.